Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL)

Bone Marrow Transplant. 2017 Feb;52(2):321-322. doi: 10.1038/bmt.2016.275. Epub 2016 Nov 28.

Authors

N Shah¹, S Rauenzahn², L Veltri¹, S Wen³, M Craig¹, M Hamadani⁴, A S Kanate¹, A Cumpston^{1

5}

Affiliations

¹ Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV, USA.
² Department of Internal Medicine, West Virginia University, Morgantown, WV, USA.
³ Department of Biostatistics, West Virginia University, Morgantown, WV, USA.
⁴ Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
⁵ Department of Pharmacy, West Virginia University Medicine, Morgantown, WV, USA.

PMID: 27892948
DOI: 10.1038/bmt.2016.275

No abstract available

Publication types

Clinical Trial

MeSH terms

Adult
Aged
Autografts
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation*
Humans
Lymphoma, Non-Hodgkin / mortality*
Lymphoma, Non-Hodgkin / therapy*
Male
Middle Aged
Retrospective Studies
Thiotepa / administration & dosage*
Thiotepa / adverse effects
Time Factors

Substances

Thiotepa